PURPOSE: Appendiceal neoplasms are heterogeneous and are often treated with chemotherapy similarly to colorectal cancer (CRC). Genomic profiling was performed on 703 appendiceal cancer specimens to compare the mutation profiles of appendiceal subtypes to CRC and other cancers, with the ultimate aim to identify potential biomarkers and novel therapeutic targets. METHODS: Tumor specimens were submitted to a Clinical Laboratory Improvement Amendments-certified laboratory (Foundation Medicine, Cambridge, MA) for hybrid-capture-based sequencing of 3,769 exons from 315 cancer-related genes and 47 introns of 28 genes commonly rearranged in cancer. Interactions between genotype, histologic subtype, treatment, and overall survival (OS) were analyzed in a clinically annotated subset of 76 cases. RESULTS: There were five major histopathologic subtypes: mucinous adenocarcinomas (46%), adenocarcinomas (30%), goblet cell carcinoids (12%), pseudomyxoma peritonei (7.7%), and signet ring cell carcinomas (5.2%). KRAS (35% to 81%) and GNAS (8% to 72%) were the most frequent alterations in epithelial cancers; APC and TP53 mutations were significantly less frequent in appendiceal cancers relative to CRC. Low-grade and high-grade tumors were enriched for GNAS and TP53 mutations, respectively (both χ2 P < .001). GNAS and TP53 were mutually exclusive (Bonferroni corrected P < .001). Tumor grade and TP53 mutation status independently predicted OS. The mutation status of GNAS and TP53 strongly predicted OS (median, 37.1 months for TP53 mutant v 75.8 GNAS-TP53 wild type v 115.5 GNAS mutant; log-rank P = .0031) and performed as well as grade in risk stratifying patients. CONCLUSION: Epithelial appendiceal cancers and goblet cell carcinoids show differences in KRAS and GNAS mutation frequencies and have mutation profiles distinct from CRC. This study highlights the benefit of performing molecular profiling on rare tumors to identify prognostic and predictive biomarkers and new therapeutic targets.
PURPOSE: Appendiceal neoplasms are heterogeneous and are often treated with chemotherapy similarly to colorectal cancer (CRC). Genomic profiling was performed on 703 appendiceal cancer specimens to compare the mutation profiles of appendiceal subtypes to CRC and other cancers, with the ultimate aim to identify potential biomarkers and novel therapeutic targets. METHODS: Tumor specimens were submitted to a Clinical Laboratory Improvement Amendments-certified laboratory (Foundation Medicine, Cambridge, MA) for hybrid-capture-based sequencing of 3,769 exons from 315 cancer-related genes and 47 introns of 28 genes commonly rearranged in cancer. Interactions between genotype, histologic subtype, treatment, and overall survival (OS) were analyzed in a clinically annotated subset of 76 cases. RESULTS: There were five major histopathologic subtypes: mucinous adenocarcinomas (46%), adenocarcinomas (30%), goblet cell carcinoids (12%), pseudomyxoma peritonei (7.7%), and signet ring cell carcinomas (5.2%). KRAS (35% to 81%) and GNAS (8% to 72%) were the most frequent alterations in epithelial cancers; APC and TP53 mutations were significantly less frequent in appendiceal cancers relative to CRC. Low-grade and high-grade tumors were enriched for GNAS and TP53 mutations, respectively (both χ2 P < .001). GNAS and TP53 were mutually exclusive (Bonferroni corrected P < .001). Tumor grade and TP53 mutation status independently predicted OS. The mutation status of GNAS and TP53 strongly predicted OS (median, 37.1 months for TP53 mutant v 75.8 GNAS-TP53 wild type v 115.5 GNAS mutant; log-rank P = .0031) and performed as well as grade in risk stratifying patients. CONCLUSION: Epithelial appendiceal cancers and goblet cell carcinoids show differences in KRAS and GNAS mutation frequencies and have mutation profiles distinct from CRC. This study highlights the benefit of performing molecular profiling on rare tumors to identify prognostic and predictive biomarkers and new therapeutic targets.
Authors: Elizabeth M Gleeson; Rebecca Feldman; Beth L Mapow; Lynn T Mackovick; Kristine M Ward; William F Morano; Rene R Rubin; Wilbur B Bowne Journal: Am J Clin Oncol Date: 2018-08 Impact factor: 2.339
Authors: Aatur D Singhi; Jon M Davison; Haroon A Choudry; James F Pingpank; Steven A Ahrendt; Matthew P Holtzman; Amer H Zureikat; Herbert J Zeh; Lekshmi Ramalingam; Geeta Mantha; Marina Nikiforova; David L Bartlett; Reetesh K Pai Journal: Hum Pathol Date: 2014-05-08 Impact factor: 3.466
Authors: Norman J Carr; Thomas D Cecil; Faheez Mohamed; Leslie H Sobin; Paul H Sugarbaker; Santiago González-Moreno; Panos Taflampas; Sara Chapman; Brendan J Moran Journal: Am J Surg Pathol Date: 2016-01 Impact factor: 6.394
Authors: Michelle D Reid; Olca Basturk; Walid L Shaib; Yue Xue; Serdar Balci; Hye-Jeong Choi; Gizem Akkas; Bahar Memis; Brian S Robinson; Bassel F El-Rayes; Charles A Staley; Christopher A Staley; Joshua H Winer; Maria C Russell; Jessica H Knight; Michael Goodman; Alyssa M Krasinskas; Volkan Adsay Journal: Mod Pathol Date: 2016-06-24 Impact factor: 7.842
Authors: G Nishikawa; S Sekine; R Ogawa; A Matsubara; T Mori; H Taniguchi; R Kushima; N Hiraoka; K Tsuta; H Tsuda; Y Kanai Journal: Br J Cancer Date: 2013-02-12 Impact factor: 7.640
Authors: Travis Edward Grotz; Richard E Royal; Paul F Mansfield; Michael James Overman; Gary N Mann; Kristen Ashlee Robinson; Karen A Beaty; Safiea Rafeeq; Auerlio Matamoros; Michelle W Taggart; Keith Francis Fournier Journal: World J Gastrointest Oncol Date: 2017-09-15
Authors: Ashley K Clift; Oskar Kornasiewicz; Panagiotis Drymousis; Omar Faiz; Harpreet S Wasan; James M Kinross; Thomas Cecil; Andrea Frilling Journal: Endocr Connect Date: 2018-01-15 Impact factor: 3.335